259 related articles for article (PubMed ID: 12224986)
1. Adverse cutaneous reactions to hydroxychloroquine are more common in patients with dermatomyositis than in patients with cutaneous lupus erythematosus.
Pelle MT; Callen JP
Arch Dermatol; 2002 Sep; 138(9):1231-3; discussion 1233. PubMed ID: 12224986
[TBL] [Abstract][Full Text] [Related]
2. Antimalarial drug toxicities in patients with cutaneous lupus and dermatomyositis: A retrospective cohort study.
Mittal L; Zhang L; Feng R; Werth VP
J Am Acad Dermatol; 2018 Jan; 78(1):100-106.e1. PubMed ID: 28989103
[TBL] [Abstract][Full Text] [Related]
3. Association Between Autoantibody Phenotype and Cutaneous Adverse Reactions to Hydroxychloroquine in Dermatomyositis.
Wolstencroft PW; Casciola-Rosen L; Fiorentino DF
JAMA Dermatol; 2018 Oct; 154(10):1199-1203. PubMed ID: 30140893
[TBL] [Abstract][Full Text] [Related]
4. Adverse cutaneous drug reactions with antimalarials in cutaneous lupus and dermatomyositis: A retrospective cohort study.
Gonzalez CD; Hansen C; Clarke JT
J Am Acad Dermatol; 2019 Sep; 81(3):859-860. PubMed ID: 31085265
[No Abstract] [Full Text] [Related]
5. Lupus erythematosus tumidus: response to antimalarial treatment in 36 patients with emphasis on smoking.
Kreuter A; Gaifullina R; Tigges C; Kirschke J; Altmeyer P; Gambichler T
Arch Dermatol; 2009 Mar; 145(3):244-8. PubMed ID: 19289751
[TBL] [Abstract][Full Text] [Related]
6. Adverse cutaneous reactions secondary to hydroxychloroquine in patients with dermatomyositis, lupus erythematosus, and lichen planopilaris.
Akabane AL; Smith GP
J Am Acad Dermatol; 2021 Oct; 85(4):1046-1047. PubMed ID: 33607179
[No Abstract] [Full Text] [Related]
7. Combined mepacrine-hydroxychloroquine treatment in patients with systemic lupus erythematosus and refractory cutaneous and articular activity.
Ugarte A; Porta S; Ríos R; Martinez-Zapico A; Ortego-Centeno N; Agesta N; Ruiz-Irastorza G
Lupus; 2018 Sep; 27(10):1718-1722. PubMed ID: 29635998
[TBL] [Abstract][Full Text] [Related]
8. Changing antimalarial agents after inefficacy or intolerance in patients with cutaneous lupus erythematosus: A multicenter observational study.
Chasset F; Arnaud L; Jachiet M; Monfort JB; Bouaziz JD; Cordoliani F; Bagot M; Barbaud A; Francès C
J Am Acad Dermatol; 2018 Jan; 78(1):107-114.e1. PubMed ID: 29061479
[TBL] [Abstract][Full Text] [Related]
9. Experience with the use of hydroxychloroquine for the treatment of lupus erythematosus.
Momose Y; Arai S; Eto H; Kishimoto M; Okada M
J Dermatol; 2013 Feb; 40(2):94-7. PubMed ID: 23216212
[TBL] [Abstract][Full Text] [Related]
10. Early cutaneous eruptions after oral hydroxychloroquine in a lupus erythematosus patient: A case report and review of the published work.
Matsuda T; Ly NTM; Kambe N; Nguyen CTH; Ueda-Hayakawa I; Son Y; Okamoto H
J Dermatol; 2018 Mar; 45(3):344-348. PubMed ID: 29239026
[TBL] [Abstract][Full Text] [Related]
11. Combination antimalarials in the treatment of cutaneous dermatomyositis: a retrospective study.
Ang GC; Werth VP
Arch Dermatol; 2005 Jul; 141(7):855-9. PubMed ID: 16027300
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic efficacy and adverse events of hydroxychloroquine administration in Japanese systemic/cutaneous lupus erythematosus patients.
Kishi C; Motegi SI; Yasuda M; Ishikawa O
J Dermatol; 2018 Aug; 45(8):1020-1022. PubMed ID: 30133802
[No Abstract] [Full Text] [Related]
13. The quinacrine experience in a population of patients with cutaneous lupus erythematosus and dermatomyositis.
Mittal L; Werth VP
J Am Acad Dermatol; 2017 Aug; 77(2):374-377. PubMed ID: 28711090
[No Abstract] [Full Text] [Related]
14. Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis.
Chang AY; Piette EW; Foering KP; Tenhave TR; Okawa J; Werth VP
Arch Dermatol; 2011 Nov; 147(11):1261-7. PubMed ID: 21768444
[TBL] [Abstract][Full Text] [Related]
15. Varied responses to and efficacies of hydroxychloroquine treatment according to cutaneous lupus erythematosus subtypes in Japanese patients.
Ototake Y; Yamaguchi Y; Kanaoka M; Akita A; Ikeda N; Aihara M
J Dermatol; 2019 Apr; 46(4):285-289. PubMed ID: 30719729
[TBL] [Abstract][Full Text] [Related]
16. Steady-state pharmacokinetics of hydroxychloroquine in patients with cutaneous lupus erythematosus.
Al-Rawi H; Meggitt SJ; Williams FM; Wahie S
Lupus; 2018 Apr; 27(5):847-852. PubMed ID: 28862574
[TBL] [Abstract][Full Text] [Related]
17. Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus: a French multicenter prospective study.
Francès C; Cosnes A; Duhaut P; Zahr N; Soutou B; Ingen-Housz-Oro S; Bessis D; Chevrant-Breton J; Cordel N; Lipsker D; Costedoat-Chalumeau N
Arch Dermatol; 2012 Apr; 148(4):479-84. PubMed ID: 22508872
[TBL] [Abstract][Full Text] [Related]
18. The association of the two antimalarials chloroquine and quinacrine for treatment-resistant chronic and subacute cutaneous lupus erythematosus.
Feldmann R; Salomon D; Saurat JH
Dermatology; 1994; 189(4):425-7. PubMed ID: 7873836
[TBL] [Abstract][Full Text] [Related]
19. Impact of smoking in cutaneous lupus erythematosus.
Piette EW; Foering KP; Chang AY; Okawa J; Ten Have TR; Feng R; Werth VP
Arch Dermatol; 2012 Mar; 148(3):317-22. PubMed ID: 22105815
[TBL] [Abstract][Full Text] [Related]
20. The effect of increasing the dose of hydroxychloroquine (HCQ) in patients with refractory cutaneous lupus erythematosus (CLE): An open-label prospective pilot study.
Chasset F; Arnaud L; Costedoat-Chalumeau N; Zahr N; Bessis D; Francès C
J Am Acad Dermatol; 2016 Apr; 74(4):693-9.e3. PubMed ID: 26850655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
